智通财经APP获悉，申万宏源发布研报称，从作用机制来看，小核酸药物直接作用于mRNA层面，能够 靶向传统药物难以触及的"不可成药"靶点，为许多难治性疾病提供了全新的治疗思路。在技术持续进 步、上市批准及临床验证不断增加的推动下，预计全球小核酸药物市场将加速增长，从2023年起以 26.1%的复合年增长率在2033年达到467亿美元。目前国内多款自研产品正处于临床一二期，建议关注 后续临床数据的读出以及潜在的海外授权。 目前全球小核酸药物共获批22款(其中3款已退市)，主要集中在脊髓性肌萎缩症(SMA)、杜氏肌营养不良 (DMD)、转甲状腺素蛋白淀粉样变(ATTR)等罕见病领域，近几年随着小核酸药物在高血脂、乙肝、高 血压等领域的数据读出，小核酸药从罕见病领域向慢性病、常见病跨越的趋势已经展现，市场有望加速 扩容。根据沙利文报告数据，全球小核酸药物市场规模从2019年的27亿美元增长到2023年的46亿美元， 复合年增长率为14.3%。在技术持续进步、上市批准及临床验证不断增加的推动下，预计全球小核酸药 物市场将加速增长，从2023年起以26.1%的复合年增长率在2033年达到467亿美元。 国内企业加速抢占蓝 ...

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (70.75%), COSCO Shipping Energy (70.03%), and GCL-Poly Energy (69.89%) [1] - Alibaba-W, Shankai Holdings, and the Tracker Fund of Hong Kong saw the largest increases in holding amounts over the last five trading days, with increases of +77.16 billion, +28.02 billion, and +27.25 billion respectively [1] - The companies with the largest decreases in holding amounts over the same period include Hua Hong Semiconductor (-11.96 billion), Tencent Holdings (-11.37 billion), and CSPC Pharmaceutical Group (-8.06 billion) [2] Group 1: Top Holding Ratios - China Telecom (00728) has a holding ratio of 70.75% with 9.821 billion shares [1] - COSCO Shipping Energy (01138) has a holding ratio of 70.03% with 908 million shares [1] - GCL-Poly Energy (01330) has a holding ratio of 69.89% with 283 million shares [1] Group 2: Recent Increases in Holdings - Alibaba-W (09988) increased by +77.16 billion with an addition of 44.86 million shares [1] - Shankai Holdings (00412) increased by +28.02 billion with an addition of 584.91 million shares [1] - The Tracker Fund of Hong Kong (02800) increased by +27.25 billion with an addition of 100.42 million shares [1] Group 3: Recent Decreases in Holdings - Hua Hong Semiconductor (01347) decreased by -11.96 billion with a reduction of 18.05 million shares [2] - Tencent Holdings (00700) decreased by -11.37 billion with a reduction of 1.75 million shares [2] - CSPC Pharmaceutical Group (01093) decreased by -8.06 billion with a reduction of 86.71 million shares [2]

Core Insights - The report highlights the potential of small nucleic acid drugs in the weight loss market, focusing on two key targets: INHBE and ALK7, which are involved in fat metabolism regulation [5][11][12] - The UCO-SAF industry is experiencing tight supply and increasing prices due to high global demand and reduced overseas supply, with significant profit margins for SAF in China [6][17][18] - The company, Daotong Technology, is recognized as a global leader in digital repair, with strong growth prospects in its AI and robotics solutions, maintaining a "buy" rating [7][21][22] Industry Analysis - The small nucleic acid drug sector is positioned to address unmet clinical needs in weight management, with promising data from ongoing trials [12][13][14] - The SAF market is expected to grow rapidly due to increasing global demand and regulatory support, particularly in Europe and China, despite challenges in overseas supply [17][18] - The digital repair market is expanding, driven by regulatory requirements for TPMS installation and a growing vehicle population, with Daotong Technology poised to capitalize on this trend [21][24][25] Company Insights - Arrowhead and Wave are leading the development of small nucleic acid drugs, with upcoming trial data expected to provide insights into their efficacy and safety [12][14] - Frontline Bio is enhancing its competitive edge through a diversified pipeline that includes innovative drugs and high-end generics, with a focus on HIV treatment [8][27][28] - Daotong Technology's recent achievements in North America solidify its market leadership and open new opportunities in emerging markets [21][22][25]

Investment Rating - The report suggests a positive investment outlook for the small nucleic acid drug industry, highlighting its significant growth potential and advantages over traditional therapies [2]. Core Insights - The small nucleic acid drug technology is maturing, offering notable advantages such as shorter development cycles, a rich array of targets, lasting effects, and higher success rates in research and development [2]. - The global market for small nucleic acid drugs has grown from $2.7 billion in 2019 to $4.6 billion in 2023, with a compound annual growth rate (CAGR) of 14.3%. It is projected to reach $46.7 billion by 2033, growing at a CAGR of 26.1% from 2023 [2][41]. - Domestic companies are rapidly entering the market, focusing on chronic diseases rather than the traditional rare disease approach, with several products in clinical trials [2][63]. Summary by Sections 1. Introduction to Small Nucleic Acid Drugs - Small nucleic acid drugs include antisense oligonucleotides (ASO), small interfering RNA (siRNA), and aptamers, which are designed to target mRNA and regulate gene expression [8][12]. 2. Development and Commercialization of Small Nucleic Acid Drugs - The report outlines the historical development of small nucleic acid drugs, noting significant advancements post-2014 due to improved delivery systems [11][34]. - The market is currently dominated by ASO, which holds 62.5% of the market share, while siRNA has rapidly gained traction with a 36.7% share [18]. 3. Overview of Domestic and International Companies - Key domestic companies include Rebio, Shengnuo Pharmaceutical, and others, focusing on chronic diseases like cardiovascular issues and hepatitis B [2][63]. - International leaders such as Alnylam and Ionis are recognized for their pioneering work in the small nucleic acid drug space [2]. 4. Investment Analysis and Recommendations - The report recommends focusing on companies with proprietary technology platforms and advantageous pipelines, such as Rebio and Shengnuo Pharmaceutical [2].

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Views - The company is moving towards a harvest period with multiple licensing collaborations validating its platform value [1]. - The company achieved its first profit in 2024, driven by significant licensing income and a strong focus on R&D [6][22]. - The company has a robust pipeline of HER2-targeted products, with key candidates in late-stage clinical trials [6][25]. Summary by Sections 1. Technical Innovation as a Driver - The company focuses on antibody-drug conjugates (ADC) and bispecific antibodies, leveraging core technologies for differentiated cancer immunotherapy [11]. - The management team has extensive experience in research and development, ensuring innovation and operational efficiency [11][19]. - The company has secured multiple high-value licensing agreements, enhancing its platform and pipeline value [19][20]. 2. HER2-targeted Product Strategy - The company has three HER2-targeted products, including KN026 (HER2 bispecific antibody) and JSKN003 (HER2 bispecific ADC), positioned for various cancer indications [25][30]. - KN026 is expected to submit a domestic application for 2L+ HER2-positive gastric cancer by 2025, with promising clinical data [30][34]. - JSKN003 has a commercial collaboration with a partner, with a total transaction value of 30.8 billion RMB [39]. 3. JSKN016 (TROP2/HER3 ADC) Development - JSKN016 is being explored for both monotherapy and combination treatments, targeting high-expression TROP2 and HER3 in various tumors [7][25]. - The drug is in clinical phase 2, focusing on unmet needs in triple-negative breast cancer and EGFR-TKI resistant non-small cell lung cancer [7][25]. 4. Financial Performance and Projections - The company achieved a revenue of 6.4 billion RMB in 2024, a year-on-year increase of 192.6%, with a profit of 1.66 billion RMB [22][23]. - The R&D expenditure for 2024 was maintained at 4.04 billion RMB, ensuring continued investment in clinical development [22][24]. - Revenue projections for 2025-2027 are estimated at 4.58 billion RMB, 4.90 billion RMB, and 3.98 billion RMB respectively [6][25].

Group 1 - The core point of the article is that Shiyao Group has received clinical trial approval for Lankanaib monoclonal antibody injection in China [1] Group 2 - The approval marks a significant step for the company in advancing its product pipeline [1] - This development may enhance the company's competitive position in the biopharmaceutical market [1] - The clinical trial approval could lead to potential revenue growth if the product successfully reaches the market [1]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The adjustment of medical insurance and commercial insurance directories is accelerating, suggesting a favorable environment for undervalued quality stocks during market corrections [4][5] - The report emphasizes the importance of timing and stock selection in the current market, particularly after a broad rally in innovative drug stocks [4] - The upcoming ESMO conference in October is highlighted as a key event, with specific companies recommended for attention due to potential significant data releases [4] Summary by Sections Market Performance - The Hang Seng Index fell by 1.1% and the Hang Seng Healthcare Index decreased by 1.4% during the week of September 16-23, 2025, ranking 5th among 12 industry indices [4][6] - Sub-industry performance varied, with Internet medicine showing a slight increase of 0.9%, while sectors like medical devices and hospitals saw declines of 5.2% and 8.2%, respectively [4][6] Valuation Overview - The report provides a detailed valuation summary for various companies, with notable price-to-earnings (P/E) ratios for the pharmaceutical sector, such as 31.0x for prescription drugs and 14.1x for biopharmaceuticals [15] - The average P/E ratio across the sector is reported at 57.0, indicating a diverse valuation landscape [3] Institutional Holdings - As of September 23, 2025, domestic institutional holdings through Hong Kong Stock Connect remained stable at 22.2%, while foreign holdings slightly decreased to 38.7% [34][38] - The report notes a trend of increased foreign investment in innovative drug companies, with specific companies like InnoCare and Legend Biotech seeing significant increases in holdings [38][40] Regulatory Developments - The report discusses the recent adjustments to the national basic medical insurance directory and commercial insurance innovative drug directory, with a low approval rate for submitted drugs [5] - The 11th batch of national drug procurement has been announced, with new rules aimed at stabilizing clinical practices and ensuring quality [5]

Core Viewpoint - The approval of the recombinant anti-human beta-amyloid monoclonal antibody injection, Lecanemab, by the National Medical Products Administration of China marks a significant milestone for the company as it is the first biosimilar of its kind to receive clinical trial permission in China [1] Group 1: Product Details - The product is a biosimilar to Lecanemab, indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease [1] - The development of the product adheres to the relevant research guidelines for biosimilars, ensuring compliance with regulatory standards [1] Group 2: Research Findings - Pharmaceutical and non-clinical research results indicate that the product is highly similar to the reference drug in terms of quality, safety, and efficacy, supporting the initiation of subsequent clinical studies [1]

Core Viewpoint - The approval of the recombinant anti-human beta-amyloid monoclonal antibody injection, Lunakanai, by the National Medical Products Administration of China marks a significant milestone for the company as it is the first biosimilar of its kind to receive clinical trial permission in China [1] Group 1: Product Information - Lunakanai is a biosimilar to Lecanemab, classified under Category 3.3 for therapeutic biological products, and is intended for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease [1] - The development of Lunakanai adheres to the relevant research guidelines for biosimilars, ensuring compliance with regulatory standards [1] Group 2: Research Findings - Pharmaceutical and non-clinical research results indicate that Lunakanai is highly similar to the reference drug in terms of quality, safety, and efficacy, which supports the initiation of subsequent clinical studies [1]

Core Viewpoint - The approval of the recombinant anti-human beta-amyloid monoclonal antibody injection, Lunakanai, by the National Medical Products Administration of China marks a significant milestone for the company as it becomes the first biosimilar of Lunakanai to receive clinical trial permission in China [1] Company Summary - The product is a biosimilar to Leqembi, classified under Category 3.3 of therapeutic biological products, and is intended for the treatment of mild cognitive impairment and mild dementia caused by Alzheimer's disease [1] - The development of the product adheres to the relevant research guidelines for biosimilars, ensuring that it meets the necessary standards for quality, safety, and efficacy [1] - Pharmaceutical and non-clinical research results indicate that the product is highly similar to the reference drug, supporting the initiation of subsequent clinical studies [1]